3-point major cardiovascular event outcome for patients with T2D treated with dipeptidyl peptidase-4 inhibitor or glucagon-like peptide-1 receptor agonist in addition to metformin monotherapy
Antibodies Assay Kits Biology Cells cDNA Clia Kits Culture Cells Devices DNA Templates DNA Testing Elisa Kits Equipments Exosomes Gels Medium & Serums NATtrol Panel PCR Pcr Kits Peptides Recombinant Proteins Ria Kits RNA Test Kits Vector & Virus Western Blot
December 22, 2020
Background: The worldwide incidence of sort 2 diabetes (T2D) continues to extend yearly, and individuals with T2D usually require common modifications… Continue Reading